Specifications include, but are not limited to: The services provided shall be designed to control PEEHIP’s Specialty Pharmacy Drug spend in PEEHIP’s Commercial Plan. The member count for PEEHIP’s Commercial Plan for active employees is approximately 226,000. Review of the Specialty Prior Authorization (PA) process currently being utilized to ensure clinical appropriateness, proper administration, adequate documentation, and accessibility to PEEHIP review. PAs written in accordance with the package label inserts have proven to be a valuable management tool. Proposer must be able to provide PEEHIP with a web based application that is already built and functional which utilizes an easy-to-use Dashboard interface that provides drill down functionality into integrated Rx and Medical specialty claims and diagnoses. The provision of non-specialty Rx functionality and insights are also required. A thorough analysis of the most obvious and urgent drug prescription issues that can provide immediate savings. For example, our Commercial Plan may be covering drugs that are costly but that do not have proven efficacy or have inferior efficacy over lower cost alternatives. Note thatfor this initial analysis of potential drug cost savings, any non-specialty drug coverage savings areas are appropriate for disclosure to PEEHIP. Specialty drug formulary management and the development of both a clinical and financial based drug evaluation framework that encourages desired behaviors and makes sure that the most cost effective specialty drugs are being used properly by those who will truly benefit. Management and evaluation should focus not only on spend but also on ensuring that specialty drugs with severe side effects are not being prescribed inappropriately. PEEHIP is also interested in promoting preferred drugs and possibly narrowing the specialty therapeutic drug classes to drive utilization to lower cost alternatives. The analysis of both the pharmacy prescription and medical benefit specialty data for the last 12 months for the purpose of determining the most cost-effective sites of service among out-patient hospital, physician administered, or delivery through the prescription benefit. Pipeline management activities including proactive review of potential FDA approvals in specialty drugs with coverage recommendations, limitations, or exclusions. Provide PEEHIP with a program that utilizes manufacturer revenue sources/coupons/assistance programs, if and when appropriate. Exploration of appropriate and cost efficient clinical pathways for oncology. Assistance with provider and member education on the need and ways for PEEHIP to reduce its drug spend without harm to the member.